Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HTR4 | Q13639 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1484874 | 0.88 | LMNA (0.36) | HRH3L3MBTL1HTR4ADRB3ALDH1A1 | |
| SCHEMBL552030 | 0.88 | LMNA (0.36) | HRH3L3MBTL1HTR4ADRB3ALDH1A1 | |
| SCHEMBL24498679 | 0.83 | L3MBTL1 (0.37) | L3MBTL1KCNH2CARM1PRMT6ROCK2 | |
| SCHEMBL24031602 | 0.83 | L3MBTL1 (0.37) | L3MBTL1HTR4KCNH2CARM1PRMT6 | |
| SCHEMBL2617741 | 0.81 | HRH3 (0.39) | HRH3HTR4KCNH2ADRB3KDM1A | |
| SCHEMBL21101611 | 0.79 | HRH3 (0.44) | HRH3HTR4KCNH2ADRB3KDM1A | |
| SCHEMBL23568503 | 0.79 | HRH3 (0.43) | HRH3HTR4KCNH2CARM1PRMT6 | |
| SCHEMBL26306416 | 0.78 | HTR4 (0.38) | HRH3HTR4KCNH2ADRB3ALDH1A1 | |
| SCHEMBL16017510 | 0.78 | HRH3 (0.39) | HRH3HTR4KCNH2ADRB3CACNA1I | |
| SCHEMBL23709475 | 0.77 | HTR4 (0.46) | HRH3HTR4KCNH2ALDH1A1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787769-B2 | Inhibitors of influenza viral entry | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-10-17 | — | — | US | disclosed |
| WO-2023061263-A1 | SHP2 INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | 北京泰德制药股份有限公司 | 2023-04-20 | — | — | WO | disclosed |
| US-20220267275-A1 | Inhibitors of Influenza Viral Entry | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-08-25 | — | — | US | disclosed |
| WO-2020210662-A1 | SMALL MOLECULES FOR CANCER THERAPY THAT REDUCE THE EXPRESSION OF TRANSCRIPTION FACTORS KLF5 AND EGR-1 | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-10-15 | — | — | WO | disclosed |
| EP-3647313-A1 | SUBSTITUTED ARYL ETHER COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Xiamen University (CN) | 2020-05-06 | — | — | EP | disclosed |
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | Epizyme, Inc. | 2017-12-14 | — | — | US | disclosed |
| WO-2016077375-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| US-8735411-B2 | Macrocyclic benzofused pyrimidine derivatives | ABBVIE INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8436005-B2 | Macrocyclic pyrimidine derivatives | ABBOTT LABORATORIES (US) | 2013-05-07 | — | — | US | disclosed |
| US-8278313-B2 | Macrocyclic spiro pyrimidine derivatives | ABBOTT LABORATORIES (US) | 2012-10-02 | — | — | US | disclosed |
| US-20100144751-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20090253678-A1 | MACROCYCLIC PYRIMIDINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090233904-A1 | Macrocyclic Spiro Pyrimidine Derivatives | ABBOTT LABORATORIES (US) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253678-A1 | MACROCYCLIC PYRIMIDINE DERIVATIVES | DPYD, TYMS, TYMP | HRH3 3555/4885L3MBTL1 1680/4885HTR4 3428/4885 |
| US-20100144751-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | PIM1, PIM3, PIM2 | HRH3 1924/4885L3MBTL1 1756/4885HTR4 2750/4885 |
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | SHMT1, BHMT, BHMT2 | HRH3 1076/4885L3MBTL1 969/4885HTR4 807/4885 |
| US-20090233904-A1 | Macrocyclic Spiro Pyrimidine Derivatives | DPYD, TYMS, TYMP | HRH3 4454/4885L3MBTL1 2531/4885HTR4 3636/4885 |
| US-11787769-B2 | Inhibitors of influenza viral entry | NAAA, AADAC, FURIN | HRH3 183/4885L3MBTL1 3062/4885HTR4 1504/4885 |
| US-20220267275-A1 | Inhibitors of Influenza Viral Entry | NAAA, AADAC, FURIN | HRH3 183/4885L3MBTL1 3062/4885HTR4 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.